The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...

Moderna's Spikevax vaccine is the first to receive full approval for use in children aged 6 months to 11 years with a high-risk health issue.

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease ...

The Moderna vaccine can be efficient at protecting individuals and people around them from COVID-19. Learn more about it here.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...

No, side effects from all COVID-19 vaccines are mild and nothing to worry about. But let's look at the specifics and how to cope with them.

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010 ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.